Share-based Payment Arrangement, Expense in USD of RECURSION PHARMACEUTICALS, INC. from 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Recursion Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2019 to Q3 2025.
  • Recursion Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $25M, a 41.1% increase year-over-year.
  • Recursion Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $117M, a 79.9% increase year-over-year.
  • Recursion Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $79.5M, a 53.8% increase from 2023.
  • Recursion Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $51.7M, a 92.3% increase from 2022.
  • Recursion Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $26.9M, a 94.3% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

RECURSION PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $117M $25M +$7.3M +41.1% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $109M $25.8M +$9.84M +61.7% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $99.6M $35.6M +$20.1M +129% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-05
Q4 2024 $79.5M $30.3M +$14.6M +93.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-28
Q3 2024 $64.9M $17.7M +$1.4M +8.57% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $63.5M $16M +$4.57M +40.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $58.9M $15.5M +$7.24M +87.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-05
Q4 2023 $51.7M $15.7M +$8.3M +113% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-28
Q3 2023 $43.4M $16.3M +$7.69M +88.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $35.7M $11.4M +$5.89M +107% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $29.8M $8.27M +$2.93M +54.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $26.9M $7.37M +$3.32M +81.7% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-28
Q3 2022 $23.6M $8.65M +$5.56M +179% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $18M $5.5M +$524K +10.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $17.5M $5.34M +$3.65M +215% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $13.8M $4.06M +$3.08M +315% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $10.7M $3.1M +$2.27M +276% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $8.48M $4.98M +$4.21M +547% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $4.27M $1.7M +$433K +34.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $3.84M $978K Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $824K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $769K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $1.27M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12

RECURSION PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $79.5M +$27.8M +53.8% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-28
2023 $51.7M +$24.8M +92.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-28
2022 $26.9M +$13M +94.3% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-28
2021 $13.8M +$9.99M +261% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 $3.84M +$2.45M +177% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 $1.39M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.